Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ID93 + GLA-SE Vaccine in HIV Uninfected Adult TB Patients After Treatment Completion
NCT02465216Phase 2Completed
- Sponsor
- Access to Advanced Health Institute
- Start
- Jun 2015
- Primary completion
- Jan 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ID93 + GLA-SE in Tuberculosis (TB), sponsored by Access to Advanced Health Institute. Started Jun 2015; status: completed.
02
Drugs
ID93 + GLA-SE
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02465216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02465216.